具有3型与4型移行特征的髓母细胞瘤与良好预后相关
该研究采用Nanostring nCounter技术的26基因组合对68例统一治疗的髓母细胞瘤患者进行分子分型,在非WNT/非SHH肿瘤中识别出3型、4型及中间3/4型三个转录组。中间3/4型生存率最高(100%),总生存和无进展生存均优于3型(p=0.001,两者均)和4型(p=0.064和p=0.066)。
要点
- 中间3/4型患者生存率100%,总生存和无进展生存均优于3型(p=0.001)和4型(p=0.064和p=0.066)。
- 3型预后差,生存率<40%,常伴转移、大细胞/间变病理和MYCC扩增。
- 非WNT/非SHH肿瘤内存在不同风险组,现行两分组分类器可能不足以进行个体化临床分型。
核心结论
- 非WNT/非SHH髓母细胞瘤内存在不同风险组,中间3/4型患者生存率最高(100%),总生存和无进展生存均优于3型(p=0.001,两者均)和4型(p=0.064和p=0.066)。
- 现行两分组分类器可能不足以对个体患者进行恰当的临床分型。
研究设计与样本
- 采用基于Nanostring nCounter技术的26基因组合,对68例统一治疗的髓母细胞瘤患者进行分子分型。
主要发现
- 在非WNT/非SHH肿瘤中识别出3型、4型和中间3/4型三个转录组。
- 3型生存率<40%,常伴转移、大细胞/间变病理和MYCC扩增。
- 中间3/4型生存率100%,总生存和无进展生存均优于3型(p=0.001,两者均)和4型(p=0.064和p=0.066)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Group 4 tumors. The latter two groups, which can be identified by an application of multi-gene expression or methylation profiling, show sometimes ambiguous categorization and are still classified for diagnostic reason as non-SHH/non-WNT medulloblastomas in updated WHO 2016 classification. In order to better characterize non-SHH/non-WNT tumors, we applied the method based on the Nanostring nCounter Technology, using the 26 genes codeset in 68 uniformly treated medulloblastoma patients. This allowed for identification of tumors, which shared common Group 3 and Group 4 gene signatures. We recognized three transcriptional groups within non-WNT/non-SHH tumors: Group 3, Group 4 and the Intermediate 3/4 Group. Group 3, in line with previously published results, showed poor prognosis with survival rate < 40%, frequent metastases, large cell/anaplastic pathology and presence of tumors with MYCC amplification. This is in contrast to patients from the Intermediate 3/4 Group who showed the best survival rate (100%). Overall and progression free survival were better for this group than for Group 3 (p = 0.001, for both) and Group 4 (p = 0.064 and p = 0.066, respectively). Our work supports the view that within the non-WNT/non-SHH tumors different risk groups exist and that the current two groups classifier may be not sufficient for proper clinical categorization of individual patients.
引用
- Łastowska M, Trubicka J, Niemira M, et al. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis. J Neurooncol. 2018. PMID: 29427151. doi:10.1007/s11060-018-2797-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。